You can buy or sell XOMA and other stocks, options, ETFs, and crypto commission-free!
XOMA Corp. engages in the discovery and development of innovative therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. Read More The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
52 Week High
52 Week Low
Markets InsiderMar 7
XOMA Reports Fourth Quarter and Full Year 2018 Financial Results and Operating Highlights
Added seven new partner-funded programs in 2018 with potential for milestone and royalty payments Current cash balance sufficient to fund operations for multiple years EMERYVILLE, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) announced its fourth quarter and full-year 2018 financial results and business highlights. “In 2018, we completed the first transaction under our royalty-aggregator business model, adding seven assets being developed by Merck and Incyte, bringing our roy...
Associated PressMar 5
XOMA to Present at the Cowen and Company 39th Annual Health Care Conference
EMERYVILLE, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company’s business at the Cowen and Company 39th Annual Health Care Conference in Boston, Massachusetts. The presentation will take place on Tuesday, March 12, 2019, at 12:00PM ET, and can be accessed via a live webcast on the investor relations page of XOMA’s website at www.xoma.com. An archived version of the webcast will be availabl...
Expected May 9, Pre-Market